Virtus Biotech Clinical Trials ETF
BBC
19 hedge funds and large institutions have $11.4M invested in Virtus Biotech Clinical Trials ETF in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4.58% less ownership
Funds ownership: 41.44% → 36.86% (-4.6%)
10% less funds holding
Funds holding: 21 → 19 (-2)
25% less capital invested
Capital invested by funds: $15.2M → $11.4M (-$3.79M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$93.1K |
| 2 |
LPL Financial
San Diego,
California
|
+$74.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$66.6K |
| 4 |
Morgan Stanley
New York
|
+$30K |
| 5 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$8.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$667K |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$633K |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$377K |
| 4 |
HI
Harbour Investments
Madison,
Wisconsin
|
-$120K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$54K |
BBC Hedge Fund Activity: Q4 2021 in Review
19 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q4 2021, worth a combined $11.4M — down 25% from $15.2M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBC and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, adding an estimated $93.1K. The largest seller was Royal Bank of Canada, cutting an estimated $667K.
- 19 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q4 2021, down from 21 in Q3 2021.
- Funds reported $11.4M of Virtus Biotech Clinical Trials ETF stock for Q4 2021, down 25% quarter-over-quarter.
- 2 funds opened new Virtus Biotech Clinical Trials ETF positions in Q4 2021 and 4 closed out, a net change of -2 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q4 2021 was UBS Group, an estimated $93.1K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q4 2021 was Royal Bank of Canada, an estimated $667K sold.
Based on aggregated 13F filings for Q4 2021.